Skip to content

Intravenous Remifentanil for Labor Analgesia

Remifentanil Intravenous Patient-controlled Labor Analgesia for Nulliparous Women

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00710086
Acronym
IRELAN
Enrollment
1000
Registered
2008-07-04
Start date
2008-07-31
Completion date
2009-09-30
Last updated
2009-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Labor Pain

Keywords

Remifentanil, Patient-controlled analgesia, Intravenous analgesia

Brief summary

Labor analgesia is an essential health caring procedure for women. However, epidural analgesia cannot be performed on all subjects for different contraindications, such as lower platelet counter, back infection at the puncture site, and fear of epidural injection etc. Therefore, intravenous analgesia is an alternative for such conditions. Given the influence of intravenous administration of drugs on fetus, the drug selection is very important. Remifentanil, a super-short efficacious opioid, can last for 3-4 minutes after injection, which is similar in both maternal and fetal environment. Thus the fetus-associated side effects would be less than other drugs. The investigators hypothesized that remifentanil would be a superior intravenous drug used with patient-controlled technique for labor analgesia.

Interventions

DRUGHydromorphone

Intravenous administration of hydromorphone 1mg at the patient's request if they felt uterine contraction pain

DRUGRemifentanil

Remifentanil intravenous PCA: 0.2μg/kg, lockout time interval 2 minutes, continuous infusion rate 0.2-0.8μg/kg/min.

Sponsors

HRSA/Maternal and Child Health Bureau
CollaboratorFED
Nanjing Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

1. Nulliparous women 2. \> 18 years and \< 45 years 3. Spontaneous labor 4. Analgesia request 5. Epidural puncture contraindications 6. Tendency of bleeding

Exclusion criteria

1. Allergy to opioids, a history of the use of centrally-acting drugs of any sort, chronic pain and psychiatric diseases records 2. Participants younger than 18 years or older than 45 years 3. Those who were not willing to or could not finish the whole study at any time 4. Using or used in the past 14 days of the monoamine oxidase inhibitors 5. Alcohol addictive or narcotic dependent patients were excluded for their influence on the analgesic efficacy of the epidural analgesics 6. Subjects with a nonvertex presentation or scheduled induction of labor 7. Cervical dilation was 5.0cm or greater before performing epidural puncture and catheterization 8. Diagnosed diabetes mellitus and pregnancy-induced hypertension 9. Twin gestation and breech presentation

Design outcomes

Primary

MeasureTime frame
Maternal Visual Analog Scale (VAS) rating of painPrior to analgesia, latent phrase, active phrase, second stage of labor, posterior to vaginal delivery

Secondary

MeasureTime frame
Rate of instrument-assisted deliveryAnalgesia initiation (0 min) to successful vaginal delivery (this time period underwent changing in different individuals)
Indications of cesarean deliveryAnalgesia initiation (0 min) to cesarean section (this time period underwent changing in different individuals)
Duration of analgesiaInitiation of analgesia (0 min) to the disappearance of sensory block (this time period underwent changing in different individuals)
Maternal satisfaction with analgesiaAt the end of the vaginal delivery (this time period underwent changing in different individuals)
Maternal oral temperatureAnalgesia initiation (0 min) to successful vaginal delivery (this time period underwent changing in different individuals)
Use of oxytocin after analgesiaAnalgesia initiation (0 min) to successful vaginal delivery (this time period underwent changing in different individuals)
Maximal oxytocin doseAt the end of vaginal delivery (this time period underwent changing in different individuals)
Rate of cesarean deliveryAnalgesia initiation (0 min) to successful vaginal delivery (this time period underwent changing in different individuals)
Neonatal one-minute Apgar scaleAt the first minute of baby was born
Neonatal five-minute Apgar scaleAt the fifth minute of baby was born
Umbilical-cord gases analysisAt the time baby was born (0 min)
Neonatal sepsis evaluationAfter the baby was born (15 min after delivery)
Neonatal antibiotic treatmentAfter the baby was born (one day after delivery)
Incidence of maternal side effectsAnalgesia initiation (0 min) to successful vaginal delivery (this time period underwent changing in different individuals)
Breastfeeding success at 6 weeks after vaginal deliveryAt the sixth week after successful delivery

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026